Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.67 USD | -2.14% | -5.70% | -43.46% |
Jun. 05 | QuidelOrtho Seeks Inorganic Options | CI |
Jun. 05 | Transcript : QuidelOrtho Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 01:20 PM |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.46% | 2.79B | C+ | ||
-26.77% | 16.48B | A | ||
+22.46% | 1.94B | - | ||
-12.32% | 1.46B | - | ||
+31.49% | 1.33B | B+ | ||
-16.15% | 966M | - | ||
+1.33% | 791M | - | ||
-31.07% | 788M | - | C- | |
-25.95% | 620M | B+ | ||
+20.28% | 577M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QDEL Stock
- Ratings QuidelOrtho Corporation